Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Search
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
SIRPα antagonist
SIRPα antagonist
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Microbial expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Partnering in Biotherapeutics MAY 2023 Corp
Partnering in Biotherapeutics JUNE 2023 CORP
Biotherapeutics Modalities Infographic FINAL.pdf
Partnering in Biotherapeutics Technologies MARCH 2023 Corporate
Partnering in Biotherapeutics Technologies MARCH 2023 Corporate
biotherapeutic_technologies_flyer_bio_05-2020.pdf
biotherapeutic_technologies_flyer_q4_2020.pdf
Biotherapeutic_Technologies_Flyer_BIO_2022.pdf
Partnering in Biotherapeutics MAY 2024 CORP .pdf
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.